Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by narmacon Dec 23, 2022 1:02pm
62 Views
Post# 35189837

RE:RE:RE:Some Thoughts in Summary

RE:RE:RE:Some Thoughts in Summary,.,.,I dont hold any interest in xB3 at this stage,,,,nor does anyone else out there,,,,,,it has created ZERO value being expressed in share price,,,,,,it is dead technology,,,,, unless a partner releaseses positive data down the road, and I dont fear that happening.  Management just never told their shareholders that!!,,,,As far as I can read between the lines xB3 will otherwise just fade away into the sunset here until such time, if ever it happens. We are most likely back to the RH days where clinic work was not on the books.

We missed all back in 2016 when BTI shares were trading at $2.  Maybe at the time the business model was all licensing and cash infusion was not front row center,,,.maybe,,,,but we now see there has been a major failure in securing the future of BTI since that time. Shame!
<< Previous
Bullboard Posts
Next >>